Policy | September 06, 2021
TB Alliance partners with Lupin for non-exclusive anti-TB drug
According to WHO, over 1.5 million people died of TB in 2020
According to WHO, over 1.5 million people died of TB in 2020
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
Subscribe To Our Newsletter & Stay Updated
